Neogenomics (NEO) Shares Outstanding (Weighted Average) (2016 - 2026)
Neogenomics filings provide 17 years of Shares Outstanding (Weighted Average) readings, the most recent being $129.2 million for Q1 2026.
- On a quarterly basis, Shares Outstanding (Weighted Average) rose 1.41% to $129.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $129.2 million, a 1.41% increase, with the full-year FY2025 number at $128.1 million, up 1.14% from a year prior.
- Shares Outstanding (Weighted Average) hit $129.2 million in Q1 2026 for Neogenomics, up from $128.1 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $129.2 million in Q1 2026 to a low of $123.6 million in Q1 2022.
- Median Shares Outstanding (Weighted Average) over the past 5 years was $126.1 million (2024), compared with a mean of $126.1 million.
- Biggest five-year swings in Shares Outstanding (Weighted Average): grew 6.4% in 2022 and later grew 0.64% in 2024.
- Neogenomics' Shares Outstanding (Weighted Average) stood at $124.2 million in 2022, then grew by 1.03% to $125.5 million in 2023, then grew by 0.92% to $126.7 million in 2024, then rose by 1.14% to $128.1 million in 2025, then increased by 0.83% to $129.2 million in 2026.
- The last three reported values for Shares Outstanding (Weighted Average) were $129.2 million (Q1 2026), $128.1 million (Q4 2025), and $128.4 million (Q3 2025) per Business Quant data.